Lateral flow device for diagnosing alzheimer's disease using the t14 peptide
OwnerSusan GREENFIELD, Sara Garcia-Ratesinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerSusan GREENFIELD, Sara Garcia-Ratesinventors
Estimating the term…
The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and/or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and/or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.
A lateral flow method of diagnosing or prognosing a neurodegenerative disorder in a subject, the method comprising using lateral flow to detect, in a sample obtained from a test subject, a peptide comprising or consisting of SEQ ID No:
A lateral flow apparatus, for diagnosing or prognosing neurodegenerative disorder in a subject, the apparatus comprising a lateral flow support for detecting, in a sample obtained from a test subject, a peptide comprising or consisting of SEQ ID No:
A method or apparatus according to any preceding claim, comprising diagnosing a neurodegenerative disorder.
A method or apparatus according to any preceding claim, comprising diagnosing pre-symptomatic conditions in the test subject.
A method or apparatus according to any preceding claim, comprising conducting a clinical trial to monitor the activity or efficacy of a drug administered to the test subject, and preferably determine how much the subject has, or has not, deteriorated since an earlier test.
A method or apparatus according to any preceding claim, wherein the peptide comprising or consisting of SEQ ID No:
A method or apparatus according to any preceding claim, comprising determining the concentration of soluble peptide comprising or consisting of SEQ ID No:
A method or apparatus according to any preceding claim, comprising means for determining, in the sample obtained from the test subject, the concentration of SEQ ID No:
A method or apparatus according to any preceding claim, wherein the sample is nasal discharge or fluid, saliva, blood, venous blood, arterial blood, blood plasma, blood serum, capillary blood, non-venous blood, non-arterial blood, pin-prick blood, spinal fluid, urine, sweat, tears, breast aspirate, prostate fluid, seminal fluid, vaginal fluid, stool, cervical scraping, cytes, amniotic fluid, intraocular fluid, mucous, moisture in breath, animal tissue, cell lysates, tumour tissue, hair, skin, buccal scrapings, lymph, interstitial fluid, nails, bone marrow, cartilage, prions, bone powder, ear wax, or combinations thereof.
A method or apparatus according to any preceding claim, comprising an inhibition lateral flow test.
A method or apparatus according to any preceding claim, comprising a sandwich lateral flow test.
A method or apparatus according to any preceding claim, wherein the apparatus comprises an LFT cartridge, which comprises a sample pad onto which the sample is placed, and wherein the LFT cartridge comprises anti-T14 antibodies, which are optionally labelled with a labelling moiety, such as a gold nanoparticle.
A method or apparatus according to any preceding claim, wherein the method or apparatus is qualitative, semi-quantitative or quantitative.
A method of diagnosing or prognosing a neurodegenerative disorder in a subject, the method comprising detecting, in a nasal discharge, nasal fluid, or a pin-prick blood sample obtained from a test subject, a peptide comprising or consisting of SEQ ID No:
A neurodegenerative disorder diagnostic or prognostic apparatus, for diagnosing or prognosing neurodegenerative disorder in a subject, the apparatus comprising means for detecting, in a nasal discharge, nasal fluid, or a pin-prick blood sample obtained from a test subject, a peptide comprising or consisting of SEQ ID No:
A method or apparatus according to any preceding claim, wherein the concentration of SEQ ID No:
A method or apparatus according to any preceding claim, wherein the subject has, or is suspected of having, a neurodegenerative disease selected from a group consisting of:
A method or apparatus according to any preceding claim, wherein the subject has, or is suspected of having, Alzheimer's Disease.
A method or apparatus according to any preceding claim, wherein the methods and apparatus are used on a subject:
A method or apparatus according to any preceding claim, comprising detection of soluble and/or aggregated peptide comprising or consisting of one or more of any of T7-T13 (i.e. SEQ ID No:
A method or apparatus according to any preceding claim, comprising determining the Braak stage of the subject.
A method or apparatus according to any preceding claim, comprising measuring the rate of cognitive decline by a Mini Mental State Examination (MMSE) score and/or a Preclinical Alzheimer Cognitive Composite (PACC) score.
A method or apparatus according to any preceding claim, comprising the use of lateral flow to detect of SEQ ID No:
Dependencies are inferred from the claim text.